OTCMKTS:GNMSF Genmab A/S - GNMSF Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. $392.50 +8.80 (+2.29%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$385.00▼$393.1050-Day Range$383.70▼$462.9052-Week Range$260.25▼$470.50Volume131 shsAverage Volume248 shsMarket Capitalization$25.66 billionP/E Ratio32.36Dividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort Interest About Genmab A/S (OTCMKTS:GNMSF) StockGenmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.Read More Receive GNMSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address GNMSF Stock News HeadlinesJanuary 23, 2023 | finance.yahoo.comGILD or GMAB: Which Is the Better Value Stock Right Now?January 19, 2023 | finance.yahoo.comCorrection to Company Announcement No. 1 of January 3, 2023January 29, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 2, 2023 | finance.yahoo.comGenmab to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 12, 2022 | finance.yahoo.comIs Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year?December 11, 2022 | finance.yahoo.comGenmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH MeetingDecember 3, 2022 | finance.yahoo.comTop Stocks In Multiple Industries Build Bases As Market Gains StrengthDecember 2, 2022 | finance.yahoo.comOncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue?January 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 1, 2022 | finance.yahoo.com5 Top Stocks to Tap Earnings Beat PotentialNovember 23, 2022 | finance.yahoo.com15 Biggest European Pharmaceutical CompaniesNovember 22, 2022 | finance.yahoo.comAbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority TagNovember 21, 2022 | finance.yahoo.comGenmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)November 8, 2022 | finance.yahoo.comIs Genmab (GMAB) Outperforming Other Medical Stocks This Year?October 25, 2022 | marketwatch.comScancell Shares Rise on Licensing Deal With GenmabOctober 21, 2022 | finance.yahoo.com4 Biotech Stocks Set to Outpace Q3 Earnings EstimatesSeptember 6, 2022 | finance.yahoo.comGenmab to Present at Morgan Stanley 20th Annual Global Healthcare ConferenceSeptember 3, 2022 | finance.yahoo.comGenmab A/S (GNMSF)August 5, 2022 | finance.yahoo.comGenmab, BioNTech Join Forces For Cancer Immunotherapy CandidatesAugust 5, 2022 | benzinga.comBioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy CandidatesJuly 18, 2022 | finance.yahoo.comAbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022June 13, 2022 | finance.yahoo.comAbbVie - Genmab Present Epcoritamab Data From Lymphoma TrialJune 11, 2022 | finance.yahoo.comGenmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential SymposiumJune 8, 2022 | finance.yahoo.comGenmab to Participate in a Fireside Chat at the Goldman Sachs 43rd Annual Global Healthcare ConferenceMay 11, 2022 | finance.yahoo.comGenmab Announces Financial Results for the First Quarter of 2022May 10, 2022 | finance.yahoo.comShould You Buy Genmab (GMAB) Ahead of Earnings?April 14, 2022 | finance.yahoo.comGenmab (GMAB), AbbVie's Epcoritamab Successful in LBCL StudySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GNMSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address GNMSF Company Calendar Last Earnings11/09/2022Today1/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:GNMSF CUSIPN/A CIK1434265 Webwww.genmab.com Phone(457) 020-2728Fax45-7020-2729Employees1,212Year Founded1999Profitability EPS (Most Recent Fiscal Year)$12.13 Trailing P/E Ratio32.36 Forward P/E RatioN/A P/E GrowthN/ANet Income$478.57 million Net Margins46.32% Pretax Margin60.14% Return on Equity22.78% Return on Assets20.33% Debt Debt-to-Equity RatioN/A Current Ratio9.62 Quick Ratio9.62 Sales & Book Value Annual Sales$1.35 billion Price / Sales19.02 Cash Flow$7.92 per share Price / Cash Flow49.54 Book Value$54.02 per share Price / Book7.27Miscellaneous Outstanding Shares65,370,000Free Float64,363,000Market Cap$25.66 billion OptionableNot Optionable Beta0.91 Social Links Key ExecutivesJan G. J. van de WinkelPresident & Chief Executive OfficerAnthony ManciniChief Operating Officer & Executive Vice PresidentAnthony PaganoChief Financial Officer & Executive Vice PresidentTahamtan AhmadiChief Medical Officer & Executive Vice PresidentMartin SchultzNon-Independent DirectorKey CompetitorsGenmab A/SNASDAQ:GMABHorizon Therapeutics PublicNASDAQ:HZNPMERCK Kommanditgesellschaft auf AktienOTCMKTS:MKGAFBeiGeneNASDAQ:BGNEAstellas PharmaOTCMKTS:ALPMYView All Competitors GNMSF Stock - Frequently Asked Questions How have GNMSF shares performed in 2023? Genmab A/S's stock was trading at $427.50 at the beginning of the year. Since then, GNMSF stock has decreased by 8.2% and is now trading at $392.50. View the best growth stocks for 2023 here. Are investors shorting Genmab A/S? Genmab A/S saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 67,100 shares, an increase of 527.1% from the December 31st total of 10,700 shares. Based on an average trading volume of 1,600 shares, the days-to-cover ratio is currently 41.9 days. View Genmab A/S's Short Interest. How were Genmab A/S's earnings last quarter? Genmab A/S (OTCMKTS:GNMSF) announced its quarterly earnings results on Wednesday, November, 9th. The company reported $5.31 EPS for the quarter. The company earned $553.71 million during the quarter. Genmab A/S had a trailing twelve-month return on equity of 22.78% and a net margin of 46.32%. What is Genmab A/S's stock symbol? Genmab A/S trades on the OTCMKTS under the ticker symbol "GNMSF." How do I buy shares of Genmab A/S? Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Genmab A/S's stock price today? One share of GNMSF stock can currently be purchased for approximately $392.50. How much money does Genmab A/S make? Genmab A/S (OTCMKTS:GNMSF) has a market capitalization of $25.66 billion and generates $1.35 billion in revenue each year. The company earns $478.57 million in net income (profit) each year or $12.13 on an earnings per share basis. How many employees does Genmab A/S have? The company employs 1,212 workers across the globe. How can I contact Genmab A/S? Genmab A/S's mailing address is KALVEBOD BRYGGE 43, COPENHAGEN G7, 1560. The official website for the company is www.genmab.com. The company can be reached via phone at (457) 020-2728, via email at acn@genmab.com, or via fax at 45-7020-2729. This page (OTCMKTS:GNMSF) was last updated on 1/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.